focus -WSS

focus

author：comprehensive 2025-09-14 21:44:28 - browse：6

Humana sign -- health business coverage from STAT — Humana’s Medicare Advantage business is faring even worse than the company let on last week. Ed Reinke/AP

Humana’s Medicare Advantage business is faring even worse than the company let on last week, with “unprecedented” numbers of older adults getting medical care and busting through its tactics for holding up payment.

The country’s second largest private Medicare insurer disclosed Thursday it’s projecting roughly half the profit in 2024 that investors had expected. The news comes a week after Humana already lowered its projected 2023 profit, which still came in at north of $3 billion before taxes.

The stock market’s punishment was swift and decisive, sinking Humana’s share price by roughly 12% at midday. Outgoing CEO Bruce Broussard worked to calm nerves on the company’s investor call, reiterating his confidence in MA. Humana went all-in on the program when it announced last year it would wind down its employer business, but that comes as regulators are beefing up scrutiny of MA plans.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Hormonal contraceptives don’t actually treat endometriosis

entertainment

WSS

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

David Sabatini, ex

Extensive review finds private equity owners jack up cost of care

Stanford president’s abrupt resignation sparks debate

Surge of respiratory disease in China has likely explanation

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

leisure time

focus

entertainment

The high cost of giving birth even with insurance

A new ‘biological computer' targets cancer while sparing healthy cells

Anesthesiologist group: stop taking Ozempic before surgery

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Hepatitis C has a cure — but many Americans still lack access to it

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Wildfire smoke exposes gaps in outdoor worker protections

In key trial, Verve's treatment lowers cholesterol levels in patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Anthos stroke drug appears safer than common blood thinner

explore

Extensive review finds private equity owners jack up cost of care

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Stanford president’s abrupt resignation sparks debate

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Gain of function research would be limited under House proposal

entertainment

entertainment

focus

focus